New Study Published in the New England Journal of Medicine Shows COVID-19 Causes Blood Vessel Damage

New study published in the New England Journal of Medicine shows COVID-19 causes blood vessel damage. The Angiogenesis Foundation reports today that new research published in the New England Journal of Medicine shows that the respiratory virus SARS-CoV-2, which causes COVID-19, causes severe damage to blood vessels, leading to widespread thrombosis, or blood clotting, in the lung1.

The new study published in the New England Journal of Medicine was conducted by an international team of medical scientists who compared the lungs of patients who died from COVID-19 with lungs of patients who died from influenza as well as with healthy lungs donated for transplantation.  These researchers discovered an unexpected disease pattern in COVID-19 lungs: The virus invaded the cells that line blood vessels, called endothelial cells, and this was accompanied by blood clots. Compared to the flu, COVID-19 lungs had 9-fold more blood clots and the blood vessels were injured by the virus causing an unusual reaction of blood vessel growth.

“One of the great mysteries of COVID-19 has been why blood clots, or thrombosis, form in some patients who are infected,” said Dr. William Li, President and Medical Director of the Angiogenesis Foundation. “These clots can become lethal because they severely compromise blood flow not only in the lungs, but also in other organs such as the brain and heart, among other tissues.  Our research is the first to show that these clots are associated with damaged blood vessels.  The damage causes a unique healing reaction called intussusceptive angiogenesis that was found in COVID-19 at levels 30-times above normal.”

Scientists first described this phenomenon in the early 1990s as a way that blood vessels respond to injury by creating a new network of healing blood vessels2.  In the NEJM study, the researchers found an association between the more intussusceptive angiogenesis present, the longer the hospital stay of the patient suggesting that severity of COVID-19 disease is linked to blood vessel damage.  Intense inflammation was also found in all COVID-19 lungs.

“Although SARS-Cov-2 is a respiratory virus, we now see it can cause a vascular disease in COVID-19,” said Li. “The intussusceptive angiogenesis is how the body compensates when faced with thrombosis and blood vessel damage.” The injured blood vessel lining helps to explain the serious blood clotting observed in patients.  This damage may also underlie other problems seen with COVID-19, such as stroke, deep vein thrombosis, COVID toe, and damage to the heart, and also explain why anticoagulation may be helpful in preventing serious complications.  Separately, a May 6 report published in the Journal of the American College of Cardiology described how using blood thinners in patients hospitalized with COVID-19 appeared to be protective and associated with better outcomes3.

The current study highlights the need for additional research on angiogenesis and the vascular effects of COVID-19. “Our blood vessels are the lifelines for all of our organs,” said Li. “If COVID-19 damages our vessels, the long-term effects could be devastating even after the virus is cleared. Finding ways to protect our blood vessels and helping them heal could be an important dimension to COVID-19 treatment.  These interventions could involve not only medications, but importantly, dietary factors and lifestyle.”

In addition to the Angiogenesis Foundation, the following institutions were involved in this research:  Harvard Medical School (Boston); University Hospital Basel (Basel, Switzerland); KU Leuven (Leuven, Belgium), German Center for Lung Research and Hanover Medical School (Hannover, Germany); Helios University, University of Witten-Herdecke, and Johannes Gutenberg University of Mainz (Mainz, Germany).


1. Ackermann M, et. al.  Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. New Engl J Med 2020 (May 21, 2020)

2. Burri PH. Intussusceptive microvascular growth, a new mechanism of capillary network formation. EXS 1992;61:32-9.

3. Paranjpe I, et. al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 2020 May 5;S0735-1097(20)35218-9.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy